" class="no-js "lang="en-US"> University of Nottingham - Medtech Alert
Thursday, August 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
University of Nottingham | Pharmtech Focus

University of Nottingham

About University of Nottingham

University of Nottingham
The University of Nottingham is a pioneering university that transforms the lives of our 45,000 students at our campuses in the UK, China and Malaysia.

Related Story

Artificial Intelligence

 Optellum Attains CE Marking for Its Early Lung Cancer Diagnosis AI Technology | Pharmtech Focus

Optellum Attains CE Marking for Its Early Lung Cancer Diagnosis AI Technology

March 30 2022

Optellum, an Oxford-based medtech company that provides breakthrough AI technologies to help with early diagnosis of […]